Immutep Limited (ASX:IMM)
0.0460
-0.0010 (-2.13%)
Mar 26, 2026, 3:17 PM AEST
Immutep Revenue
Immutep had revenue of 6.03M AUD in the half year ending December 31, 2025, with 185.52% growth. This brings the company's revenue in the last twelve months to 7.92M, up 62.39% year-over-year. In the fiscal year ending June 30, 2025, Immutep had annual revenue of 5.04M with 31.28% growth.
Revenue (ttm)
7.92M
Revenue Growth
+62.39%
P/S Ratio
8.74
Revenue / Employee
255.57K
Employees
31
Market Cap
69.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.04M | 1.20M | 31.28% |
| Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
| Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
| Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
| Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Botanix Pharmaceuticals | 21.92M |
| Radiopharm Theranostics | 16.28M |
| Alterity Therapeutics | 6.64M |
| Neurizon Therapeutics | 5.98M |
| Prescient Therapeutics | 4.27M |
| Arovella Therapeutics | 3.21M |
| Proteomics International Laboratories | 3.21M |
| Cynata Therapeutics | 1.69M |
Immutep News
- 7 hours ago - ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP - Newsfile Corp
- 15 hours ago - IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Trial Futility: Levi & Korsinsky - PRNewsWire
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP - GlobeNewsWire
- 1 day ago - Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP - PRNewsWire
- 3 days ago - Fraud Investigation: Levi & Korsinsky Investigates Immutep Limited (IMMP) on Behalf of Shareholders - Newsfile Corp
- 3 days ago - ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP - Newsfile Corp
- 5 days ago - IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm - Business Wire
- 6 days ago - IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewsWire